1
|
Wallyn F, Fournier C, Jounieaux V, Basille D. [The role of endoscopy in exploration of the mediastinum, indications and results]. Rev Mal Respir 2023; 40:78-93. [PMID: 36528503 DOI: 10.1016/j.rmr.2022.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Accepted: 11/30/2022] [Indexed: 12/23/2022]
Abstract
Since 2005, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a standard pulmonological tool. The procedure is safe and well tolerated by patients, with minimal morbidity and almost no mortality. A previous review on the technique was published in 2012. However, over the last ten years, a number of new studies have been published on "benign" (sarcoidosis, tuberculosis…) as well as "malignant" diseases (lung cancer, metastases of extra-thoracic cancers, search for mutations and specific oncogenic markers…). These developments have led to expanded indications for EBUS-TBNA, with which it is indispensable to be familiar, in terms of "staging" as well as "diagnosis". In view of optimizing lymph node sampling, several publications have described and discussed EBUS exploration by means of newly available tools (biopsy forceps, larger needles…), and proposed interpretation of the images thereby produced. Given the ongoing evolution of linear EBUS, it seemed indispensable that information on this marvelous tool be updated. This review is aimed at summarizing the novel elements we have found the most important.
Collapse
Affiliation(s)
- F Wallyn
- Service endoscopie respiratoire. CHRU Lille, clinique de pneumologie, 59000 Lille, France
| | - C Fournier
- Service endoscopie respiratoire. CHRU Lille, clinique de pneumologie, 59000 Lille, France
| | - V Jounieaux
- Unité de soins continus cardio-thoracique-vasculaire-respiratoire. service de pneumologie, CHU d'Amiens-Picardie, 80054 Amiens, France
| | - D Basille
- Unité de soins continus cardio-thoracique-vasculaire-respiratoire. service de pneumologie, CHU d'Amiens-Picardie, 80054 Amiens, France.
| |
Collapse
|
2
|
Kirkove D, Barthelemy N, Coucke P, Mievis C, Ben Mustapha S, Jodogne S, Dardenne N, Donneau AF, Pétré B. [Feasibility study: The medical imaging as a tool for therapeutic education in radiotherapy]. Cancer Radiother 2022; 26:1034-1044. [PMID: 35843782 DOI: 10.1016/j.canrad.2022.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 03/18/2022] [Accepted: 04/01/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE Assess the feasibility of a randomized controlled trial (RCT) exploring the use of medical imaging as a therapeutic education (TPE) intervention in external radiation therapy. MATERIALS AND METHODS Experimental feasibility trial of "RCT" type carried out in a single-center, between November 2019 and March 2020, following adult patients treated by thoracic radiotherapy. In addition to the information usually given, the experimental group benefited from an intervention consisting in the visualization of their own medical images using the open-source software "Stone of Orthanc". RESULTS Forty-nine patients were recruited with a refusal rate of 8.16% (4/49). 20 patients were withdrawn from the study for health reasons (COVID), 10 for medical reasons. All the remaining 15 participants completed the process. Although not significant, the experimental group showed a median gain in the perception of knowledge compared to the control group (+ 1.9 (1.6 - 2.2)) vs (+ 1.4 (1.4 - 1.8)), as well as a decrease in scores related to anxiety (- 3.0 (-4.5 - (-2.0)) vs - 1.0 (-5.0 - 0.0)) and emotional distress ((- 5.0 (- 7.5 - (- 3.5)) vs (- 2.0 (- 5.0 - (- 1.0)) A significant reduction (p=0.043) is observed for the depression score ((- 2.0 (-3.0 - (-1.5)) vs (0.0 (0.0 - 0.0)). CONCLUSION This study demonstrates the feasibility of the project, with promising preliminary results. Some adaptations in order to conduct a larger-scale RCT are highlighted.
Collapse
Affiliation(s)
- D Kirkove
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique.
| | - N Barthelemy
- Service Equipe mobile de soins palliatifs, Oncologie Radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - P Coucke
- Département de Physique Médicale, Service médical de radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - C Mievis
- Service Equipe mobile de soins palliatifs, Oncologie Radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - S Ben Mustapha
- Service Equipe mobile de soins palliatifs, Oncologie Radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - S Jodogne
- Institute of Information and Communication Technologies, Electronics and Applied Mathematics, Louvain School of Engineering, 1348 Louvain-la-Neuve, Belgique
| | - N Dardenne
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique; Centre Hospitalo-Universitaire Biostatistique et méthodes de recherche (B-STAT), Faculté de Médecine, Université de Liège, B23/Avenue Hippocrate, n°13, 4000 Liège, Belgique
| | - A-F Donneau
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique; Centre Hospitalo-Universitaire Biostatistique et méthodes de recherche (B-STAT), Faculté de Médecine, Université de Liège, B23/Avenue Hippocrate, n°13, 4000 Liège, Belgique
| | - B Pétré
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique
| |
Collapse
|
3
|
Evaluation of Microscopic Tumour Extension in Localized Stage Non-Small-Cell Lung Cancer for Stereotactic Radiotherapy Planning. Cancers (Basel) 2022; 14:cancers14051282. [PMID: 35267589 PMCID: PMC8909894 DOI: 10.3390/cancers14051282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/22/2022] [Accepted: 03/01/2022] [Indexed: 02/04/2023] Open
Abstract
Background: Stereotactic radiotherapy for localised stage non-small-cell lung carcinoma (NSCLC) is an alternative indication for patients who are inoperable or refuse surgery. A study showed that the microscopic tumour extension (ME) of NSCLC varied according to the histological type, which allowed us to deduce adapted margins for the clinical target volume (CTV). However, to date, no study has been able to define the most relevant margins for patients with stage 1 tumours. Methods: We performed a retrospective analysis including patients with adenocarcinoma (ADC) or squamous cell carcinoma (SCC) of localised stage T1N0 or T2aN0 who underwent surgery. The ME was measured from this boundary. The profile of the type of tumour spread was also evaluated. Results: The margin required to cover the ME of a localised NSCLC with a 95% probability is 4.4 mm and 2.9 mm for SCC and ADC, respectively. A significant difference in the maximum distance of the ME between the tumour-infiltrating lymphocytes (TILs), 0−10% and 50−90% (p < 0.05), was noted for SCC. There was a significant difference in the maximum ME distance based on whether the patient had chronic obstructive pulmonary disease (COPD) (p = 0.011) for ADC. Multivariate analysis showed a statistically significant relationship between the maximum microextension distance and size with the shrinkage coefficient. Conclusion: This study definitively demonstrated that the ME depends on the pathology subtype of NSCLC. According to International Commission on Radiation Units and Measurements (ICRU) reports, 50, 62 and 83 CTV margins, proposed by these results, should be added to the GTV (Gross tumour volume). When stereotactic body radiation therapy is used, this approach should be considered in conjunction with the dataset and other margins to be applied.
Collapse
|
4
|
Guillemin F, Berger L, Lapeyre M, Bellière-Calandry A. [Dosimetric and toxicity comparison of IMRT and 3D-CRT of non-small cell lung cancer]. Cancer Radiother 2021; 25:747-754. [PMID: 34183268 DOI: 10.1016/j.canrad.2021.03.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 02/25/2021] [Accepted: 03/02/2021] [Indexed: 12/25/2022]
Abstract
PURPOSE Although three-dimensional conformal radiotherapy (3D-CRT) remains the gold standard as a curative treatment for NSCLC when surgery is not possible, intensity modulated radiotherapy (IMRT) is increasingly used routinely. The purpose of this study was to assess the clinical (immediate toxicities) and dosimetric impact of IMRT compared to 3D-CRT in the treatment of locally advanced (stages IIIA to IIIC) non-small cell lung cancer (NSCLC) treated with concomitant radiochemotherapy, while IMRT in lung cancer was implemented in the radiotherapy department of the Jean-Perrin Center. PATIENTS AND METHODS Between March 2015 and October 2019, 64 patients treated with concomitant radiochemotherapy were retrospectively included. Thirty-two received 3D-CRT and 32 IMRT. The radiotherapy prescription was 66Gy in 33 fractions of 2Gy. RESULTS IMRT has improved coverage of target volumes (V95 increased by 14.81% in IMRT; P<0.001) without increasing doses to OARs and reducing dysphagia (RR=0.67; P=0.027). Low doses to the lung were not significantly increased in IMRT (pulmonary V5 increased by 7.46% in IMRT). CONCLUSION Intensity modulated radiotherapy, compared with the standard RC3D technique, improve the coverage of target volumes without increasing the dose to the OARs. It also improves the immediate tolerance of the treatment by reducing the number of dysphagia.
Collapse
Affiliation(s)
- F Guillemin
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand cedex 1, France.
| | - L Berger
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand cedex 1, France
| | - M Lapeyre
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand cedex 1, France
| | - A Bellière-Calandry
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 5026, 63011 Clermont-Ferrand cedex 1, France
| |
Collapse
|
5
|
Meynard C, Mansuet-Lupo A, Giraud N, Boulle G, Imbault P, Guénégou-Arnoux A, Bobbio A, Durdux C, Damotte D, Giraud P. Size and Predictive Factors of Microscopic Tumor Extension in Locally Advanced Non-Small Cell Lung Cancer. Pract Radiat Oncol 2021; 11:491-501. [PMID: 34126295 DOI: 10.1016/j.prro.2021.05.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 05/21/2021] [Accepted: 05/27/2021] [Indexed: 12/25/2022]
Abstract
PURPOSE Radiation therapy for locally advanced non-small cell lung cancer (NSCLC) should treat the whole tumor, including its microscopic extensions, and protect adjacent organs at risk as much as possible. The aim of our study is to evaluate the size of microscopic tumor extension (MEmax) in NSCLC, and search for potential predictive factors. METHODS AND MATERIALS We retrospectively selected 70 patients treated with postoperative radiation therapy for a NSCLC with N2 nodal status, then 34 additional patients operated for a squamous cell lung cancer with N1 or N2 nodal status. On the digitized slides originating from the resected tumors of these 104 patients, we outlined the border of the tumor, as seen with the naked eye. We then searched for microscopic tumor extension outside of these borders with a magnification as high as 40 × and measured the maximum size of MEmax. RESULTS The median MEmax in the whole cohort was 0.85 mm (0-9.95). The MEmax was <5.3 mm in 95% of adenocarcinomas (6.5 mm in the subgroup without neoadjuvant chemotherapy) and <3.5 mm in 95% of squamous cell carcinomas (3.7 mm in the subgroup without neoadjuvant chemotherapy). After multivariate analysis, the factors associated with the size of MEmax were vascular invasion (P = .0002), histologic type, with a wider MEmax for adenocarcinomas in comparison with squamous cell carcinomas (P = .002), tumor size, which was inversely related with the size of MEmax (P = .024), and high blood pressure (P = .03). Macroscopic histologic tumor size was well correlated with both radiologic tumor size on a mediastinal setting computed tomography (correlation coefficient of 0.845) and on a parenchymal setting computed tomography (correlation coefficient of 0.836). CONCLUSIONS The clinical target volume margin, accounting for microscopic tumoral extension, could be reduced to 7 mm for adenocarcinomas and 4 mm for squamous cell carcinomas.
Collapse
Affiliation(s)
- Claire Meynard
- Radiation Oncology unit, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris University, Paris, France.
| | - Audrey Mansuet-Lupo
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris University, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Paris, France
| | - Nicolas Giraud
- Radiation Oncology Department, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France
| | - Geoffroy Boulle
- Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Paris, France
| | - Paul Imbault
- Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris University, Paris, France
| | - Armelle Guénégou-Arnoux
- Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris University, Paris, France; INSERM CIC1418-EC, Georges Pompidou European Hospital, Paris, France
| | - Antonio Bobbio
- Department of Thoracic Surgery, Assistance Publique - Hôpitaux de Paris, Cochin Hospital, Paris University, Paris, France
| | - Catherine Durdux
- Radiation Oncology unit, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris University, Paris, France
| | - Diane Damotte
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris University, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Paris, France
| | - Philippe Giraud
- Radiation Oncology unit, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris University, Paris, France
| |
Collapse
|
6
|
Antoni D, Burckel H, Noel G. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers (Basel) 2021; 13:2394. [PMID: 34063424 PMCID: PMC8156706 DOI: 10.3390/cancers13102394] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 05/12/2021] [Accepted: 05/13/2021] [Indexed: 12/25/2022] Open
Abstract
Over the past years, the identification of genetic alterations in oncogenic drivers in non-small cell lung cancer (NSCLC) has significantly and favorably transformed the outcome of patients who can benefit from targeted therapies such as tyrosine kinase inhibitors. Among these genetic alterations, anaplastic lymphoma kinase (ALK) rearrangements were discovered in 2007 and are present in 3-5% of patients with NSCLC. In addition, radiotherapy remains one of the cornerstones of NSCLC treatment. Moreover, improvements in the field of radiotherapy with the use of hypofractionated or ablative stereotactic radiotherapy have led to a better outcome for localized or oligometastatic NSCLC. To date, the effects of the combination of ALK inhibitors and radiotherapy are unclear in terms of safety and efficacy but could potently improve treatment. In this manuscript, we provide a clinical and preclinical overview of combining radiation therapy with ALK inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Collapse
Affiliation(s)
- Delphine Antoni
- Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France; (H.B.); (G.N.)
- Department of Radiotherapy, ICANS, Institut de Cancérologie Strasbourg Europe, 17 rue Albert Calmette, CEDEX, 67200 Strasbourg, France
| | - Hélène Burckel
- Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France; (H.B.); (G.N.)
| | - Georges Noel
- Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France; (H.B.); (G.N.)
- Department of Radiotherapy, ICANS, Institut de Cancérologie Strasbourg Europe, 17 rue Albert Calmette, CEDEX, 67200 Strasbourg, France
| |
Collapse
|
7
|
Briens A, Castelli J, Barateau A, Jaksic N, Gnep K, Simon A, De Crevoisier R. Radiothérapie adaptative : stratégies et bénéfices selon les localisations tumorales. Cancer Radiother 2019; 23:592-608. [DOI: 10.1016/j.canrad.2019.07.135] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Accepted: 07/16/2019] [Indexed: 12/14/2022]
|
8
|
[Lung cancer and elective nodal irradiation: A solved issue?]. Cancer Radiother 2019; 23:701-707. [PMID: 31501024 DOI: 10.1016/j.canrad.2019.06.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 06/27/2019] [Indexed: 12/25/2022]
Abstract
Lung cancer treatment is a heavy workload for radiation oncologist and that field showed many evolutions over the last two decades. The issue about target volume was raised when treatment delivery became more precise with the development of three-dimensional conformal radiotherapy. Initially based upon surgical series, numerous retrospective and prospective studies aimed to evaluate the risk of elective nodal failure of involved-field radiotherapy compared to standard large field elective nodal irradiation. In every setting, locally advanced non-small cell lung cancer, localized non-small cell lung cancer, localized small cell lung cancer, exclusive chemoradiation or postoperative radiotherapy, most of the studies showed no significant difference between involved-field radiotherapy or elective nodal irradiation with elective nodal failure rate under 5% at 2 years, provided staging had been done with modern imaging and diagnostic techniques (positron emission tomography scan, endoscopy, etc.). Moreover, if reducing irradiated volumes are safe regarding recurrences, involved-field radiotherapy allowed dose escalation while reducing acute and late oesophageal, cardiac and pulmonary toxicities. Consequently, major clinical trials involving radiotherapy initiated in the last two decades and international clinical guidelines recommended omission of elective nodal irradiation in favour of in-field radiotherapy.
Collapse
|
9
|
Giraud P, Kreps S, Tournat H, Bibault JE, Fabiano E, Feutren T, Dautruche A, Durdux C. [Stereotactic pulmonary radiotherapy: Which machine?]. Cancer Radiother 2019; 23:658-661. [PMID: 31471252 DOI: 10.1016/j.canrad.2019.07.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 07/03/2019] [Indexed: 11/29/2022]
Abstract
Stereotactic radiotherapy represents a fundamental change in the practice of radiotherapy of lung cancers. Despite the great heterogeneity of sites, techniques, and doses, most studies found a high local control rate, around 70 to 90% at 2 years, and reduced toxicity, around 5% of grade 3 at 2 years. Stereotactic radiotherapy can be realized either by a dedicated accelerator (CyberKnife®) or by a conventional accelerator associated with specific systems. The two modalities deliver a very precise irradiation whose very good results published to date are similar. Some technical characteristics specific to each type of linear accelerator could guide the choice according to the target volume treated.
Collapse
Affiliation(s)
- P Giraud
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France.
| | - S Kreps
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| | - H Tournat
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| | - J-E Bibault
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| | - E Fabiano
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| | - T Feutren
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| | - A Dautruche
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| | - C Durdux
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, 75006 Paris, France
| |
Collapse
|
10
|
De Oliveira Duarte S, Rancoule C, He MY, Baury M, Sotton S, Vallard A, Espenel S, Guy JB, Guillaume É, Vial N, Magné N, Rehailia-Blanchard A. Use of 4D-CT for radiotherapy planning and reality in France: Data from a national survey. Cancer Radiother 2019; 23:395-400. [PMID: 31331842 DOI: 10.1016/j.canrad.2019.02.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 02/15/2019] [Accepted: 02/21/2019] [Indexed: 12/25/2022]
Abstract
PURPOSE Lung and some digestive tumours move during a respiratory cycle. Four-dimensional scanography (4D-CT) is commonly used in treatment planning to account for respiratory motion. Although many French radiotherapy centres are now equipped, there are no guidelines on this subject to date. We wanted to draw up a description of the use of the 4D-CT for the treatment planning in France. METHODS AND MATERIAL We conducted a survey in all French radiotherapy centres between March and April 2017. RESULTS One hundred and seventy-two were contacted. The participation rate was 88.37%. The use of the 4D-CT seems to be common and concerned planning for 15.28% of kidney and adrenal cancers, 19.72% of pancreatic cancers, 27.78% of oesophageal cancers and 73.24% of lung cancers in case of normofractionated treatments. The use of the 4D-CT was also widespread in the case of stereotactic body radiation therapy: with 61.11% in the case of pulmonary irradiation and 34.72% in the case of hepatic irradiation. Many centres declared they carried out several 4D-CT for treatment planning (29, 55% in case of stereotactic body radiation therapy for lung tumours and 20% for liver tumours). Private centres tend to repeat 4D-CT more. CONCLUSION Although the use of the 4D-CT appears to be developing, it remains very heterogeneous. To date, the repetition of the 4D-CT has been very poorly studied and could be the subject of clinical studies, allowing to define in which indications and for which populations there is a real benefit.
Collapse
Affiliation(s)
- S De Oliveira Duarte
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France; CS 60032, École universitaire de physique et d'ingénierie, université Clermont-Auvergne, 49, boulevard François-Mitterrand, 63001 Clermont-Ferrand, France
| | - C Rancoule
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - M Y He
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France; Oncology department, Affiliated Hospital of Guizhou Medical University, China
| | - M Baury
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - S Sotton
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - A Vallard
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - S Espenel
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - J-B Guy
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - É Guillaume
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - N Vial
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - N Magné
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - A Rehailia-Blanchard
- Département de radiothérapie, Institut de cancérologie de la Loire Lucien-Neuwirth, 108, bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France.
| |
Collapse
|
11
|
Utilisation de la scanographie quadridimensionnelle : principaux aspects techniques et intérêts cliniques. Cancer Radiother 2019; 23:334-341. [DOI: 10.1016/j.canrad.2018.07.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 07/18/2018] [Accepted: 07/19/2018] [Indexed: 11/22/2022]
|
12
|
Menoux I, Le Fèvre C, Noël G, Antoni D. [Radiation-induced lung toxicity predictors after stereotactic radiation therapy for non-small cell lung carcinoma stage I]. Cancer Radiother 2018; 22:826-838. [PMID: 30337050 DOI: 10.1016/j.canrad.2017.12.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 11/08/2017] [Accepted: 12/22/2017] [Indexed: 12/19/2022]
Abstract
In case of refusal or contraindication for surgical management of a stage I non-small cell lung carcinoma, the validated alternative therapy is stereotactic irradiation. This technique reaches an equivalent tumour control rate than surgery and significantly higher than conventional radiotherapy. One of the dreaded complications is radiation induced lung toxicity (radiation pneumonitis and lung fibrosis), especially when it is symptomatic, occurring in about 10 % of cases. This article is a literature review of this complication's predictive factors.
Collapse
Affiliation(s)
- I Menoux
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France.
| | - C Le Fèvre
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France
| | - G Noël
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; EA 3430, laboratoire de radiobiologie, université de Strasbourg, fédération de médecine translationnelle de Strasbourg (FMTS), 67065 Strasbourg, France
| | - D Antoni
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; EA 3430, laboratoire de radiobiologie, université de Strasbourg, fédération de médecine translationnelle de Strasbourg (FMTS), 67065 Strasbourg, France
| |
Collapse
|
13
|
Aboudaram A, Khalifa J, Massabeau C, Simon L, Hadj Henni A, Thureau S. [Image-guided radiotherapy in lung cancer]. Cancer Radiother 2018; 22:602-607. [PMID: 30104150 DOI: 10.1016/j.canrad.2018.06.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 06/29/2018] [Indexed: 12/20/2022]
Abstract
Image-guided radiotherapy takes place at every step of the treatment in lung cancer, from treatment planning, with fusion imaging, to daily in-room repositioning. Managing tumoral and surrounding thoracic structures motion has been allowed since the routine use of 4D computed tomography (4DCT). The integration of respiratory motion has been made with "passive" techniques based on reconstruction images from 4DCT planning, or "active" techniques adapted to the patient's breathing. Daily repositioning is based on regular images, weekly or daily, low (kV) or high (MV) energy. MRI and functional imaging also play an important part in lung cancer radiation and open the way for adaptative radiotherapy.
Collapse
Affiliation(s)
- A Aboudaram
- Département de radiothérapie, institut universitaire du cancer de Toulouse-oncopôle, 1, avenue Irène-Joliot Curie, 31037 Toulouse, France.
| | - J Khalifa
- Département de radiothérapie, institut universitaire du cancer de Toulouse-oncopôle, 1, avenue Irène-Joliot Curie, 31037 Toulouse, France
| | - C Massabeau
- Département de radiothérapie, institut universitaire du cancer de Toulouse-oncopôle, 1, avenue Irène-Joliot Curie, 31037 Toulouse, France
| | - L Simon
- Département de radiothérapie, institut universitaire du cancer de Toulouse-oncopôle, 1, avenue Irène-Joliot Curie, 31037 Toulouse, France; CRCT UMR 1037 Inserm/UPS, 2, avenue Hubert-Curien, 31037 Toulouse, France
| | - A Hadj Henni
- Département de physique médicale, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France
| | - S Thureau
- Département de radiothérapie, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France; Laboratoire QuantIF, EA4108-Litis, FR CNRS 3638, 1, rue d'Amiens, 76000 Rouen, France; Département de médecine nucléaire, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France
| |
Collapse
|
14
|
Chaikh A, Calugaru V, Bondiau PY, Thariat J, Balosso J. Impact of the NTCP modeling on medical decision to select eligible patient for proton therapy: the usefulness of EUD as an indicator to rank modern photon vs proton treatment plans. Int J Radiat Biol 2018; 94:789-797. [DOI: 10.1080/09553002.2018.1486516] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Abdulhamid Chaikh
- Department of Radiation Oncology and Medical Physics, Grenoble Alpes University Hospital (CHUGA), Grenoble, France
- France HADRON National Research Infrastructure, IPNL, Lyon, France
- Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN—UMR6534—Unicaen—Normandy University, Caen, France
| | | | | | - Juliette Thariat
- Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN—UMR6534—Unicaen—Normandy University, Caen, France
- Department of Radiation Oncology, Centre François Baclesse, Caen, France
| | - Jacques Balosso
- Department of Radiation Oncology and Medical Physics, Grenoble Alpes University Hospital (CHUGA), Grenoble, France
- France HADRON National Research Infrastructure, IPNL, Lyon, France
- Department of Radiation Oncology, Centre François Baclesse, Caen, France
- University Grenoble-Alpes, Grenoble, France
| |
Collapse
|
15
|
[Stereotactic lung radiotherapy: Technical setting up on Novalis Tx ® and single centre prospective study of the 100 first malignant pulmonary nodules treated at centre Jean-Perrin]. Cancer Radiother 2017; 21:291-300. [PMID: 28522279 DOI: 10.1016/j.canrad.2017.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Revised: 01/12/2017] [Accepted: 01/26/2017] [Indexed: 11/22/2022]
Abstract
PURPOSE Description of the treatment technique of stereotactic lung radiotherapy on Novalis Tx® and prospective study of the first 100 pulmonary nodules treated at centre Jean-Perrin (France). MATERIAL AND METHODS From October 2012 to December 2015, 100 inoperable pulmonary nodules (62 stage I non-small-cell lung cancer and 38 metastases) of 90 patients with a mean age of 68.2 years (range: 46-89 years) were prospectively treated with dynamic arctherapy on Novalis Tx®. Mean gross tumour and planning target volumes were respectively 6.9 cm3 (range: 0.2-31.4 cm3) and 38.7 cm3 (range: 1.7-131 cm3), which correspond to diameters equal to 2.3cm and 4.2cm. Prescribed doses to the 80% isodose line were 54Gy in three fractions for peripheral non-small-cell lung cancer, 50Gy in five fractions for central non-small-cell lung cancer and 45Gy in three fractions for lung metastases. Clinical and radiological follow-up was done every three months with RECIST criteria for efficacy and NCI-CTCAE v4 scale for toxicity. Median follow-up was 12.5 months. RESULTS Complete response was observed in 23.8% of cases. Local control rates were 100% and 90.7% respectively at 12 and 24 months, with 96% at 24 months for stage I non-small-cell lung cancer. Overall survival rates of patients with stage I non-small-cell lung cancer were 77.4% and 73.5% at 12 and 24 months (median overall survival was 32 months). Diffusing capacity of the lungs for carbon monoxide corrected for alveolar volume below 40% was significantly associated to a poor prognostic factor on univariate analysis (P=0.00013). At least three deaths were due to an acute respiratory failure, which correspond to about 4.8% of grade 5 radiation pneumonitis. Overall survival rate for metastatic patients were 95.2% and 59.5% respectively at 12 and 24 months (median overall survival was 25 months); 23.3% of grade 2 or less radiation pneumonitis, 7.8% of grade 2 or less radiation dermatitis, 2.2% of asymptomatic ribs fracture and 3.3% of chest pains were observed. CONCLUSION Stereotactic lung radiotherapy is an effective treatment for inoperable stage I non-small-cell lung cancer and lung oligometastases of well informed and selected patients. Initial respiratory state, and especially the diffusing capacity of the lungs for carbon monoxide corrected for alveolar volume, seems to be important for tolerance.
Collapse
|